(NASDAQ: ALGS) Aligos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.
Aligos Therapeutics's earnings in 2026 is -$90,321,000.On average, 9 Wall Street analysts forecast ALGS's earnings for 2026 to be -$44,158,541, with the lowest ALGS earnings forecast at -$71,318,032, and the highest ALGS earnings forecast at -$17,348,683. On average, 9 Wall Street analysts forecast ALGS's earnings for 2027 to be -$28,303,694, with the lowest ALGS earnings forecast at -$35,470,894, and the highest ALGS earnings forecast at -$19,817,784.
In 2028, ALGS is forecast to generate -$14,685,891 in earnings, with the lowest earnings forecast at -$35,719,661 and the highest earnings forecast at $27,809,874.